greeksoup/ stock research
Stock research / United States / REGN / Filings

Regeneron Pharmaceuticals, Inc. SEC filings

Regeneron Pharmaceuticals filed 17 documents with the SEC in the last twelve months, the latest report being the 10-Q of 30 October 2026.

Filings in twelve months1710 of them 8-K news
Latest report10-Qfiled 30 Oct 2026
Latest filing10-Q30 Oct 2026
Last results, two-day move+17.6%results filed 30 Oct 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were results (8). Results came out 8 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 8 releases the share price moved 5.3% on average in the two days around results, the most on 30 Oct 2026 (+17.6%).

6 Jul 2026+3.4%$654.27 to $676.23
30 Jul 2026+9.7%$695.42 to $762.63
6 Oct 2026+2.2%$726.18 to $742.25
30 Oct 2026+17.6%$817.12 to $961.32
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

10 filings

Regeneron Pharmaceuticals's 10 news filings (8-K) were mostly about results of operations (8) and material agreement (1).

  • Results of operationsThe quarterly results release
    8 · latest 30 Oct 2026
  • Material agreementA large contract or deal was signed
    1 · latest 6 Oct 2026
  • Other eventsNews the company chose to file
    1 · latest 6 Oct 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    1 · latest 30 Sep 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 17 Jun 2026
  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    1 · latest 12 Jan 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Regeneron Pharmaceuticals, Inc. filed 17 documents with the SEC of the kinds listed here: 10 current reports (8-K), about 8 results of operations; 1 material agreement; 1 other events; 1 officer or director change; 1 shareholder vote; 3 quarterly reports (10-Q), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 annual report to shareholders (ARS), 1 annual report (10-K). The latest, filed 30 October 2026: 10-Q, quarterly report. The reports, the proxy statement and the prospectus themselves, where filed, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    30 October 202610-Qquarterly report30 September 2026EDGAR
    30 October 20268-KResults of operations30 October 2026EDGAR
    6 October 20268-KMaterial agreement, Results of operations, Other events1 October 2026EDGAR
    30 September 20268-KOfficer or director change24 September 2026EDGAR
    30 July 202610-Qquarterly report30 June 2026EDGAR
    30 July 20268-KResults of operations30 July 2026EDGAR
    6 July 20268-KResults of operations6 July 2026EDGAR
    17 June 20268-KShareholder vote12 June 2026EDGAR
    29 April 202610-Qquarterly report31 March 2026EDGAR
    29 April 20268-KResults of operations29 April 2026EDGAR
    24 April 2026DEFA14Aadditional proxy materialEDGAR
    24 April 2026DEF 14Aproxy statement12 June 2026EDGAR
    24 April 2026ARSannual report to shareholders31 December 2025EDGAR
    8 April 20268-KResults of operations8 April 2026EDGAR
    4 February 202610-Kannual report31 December 2025EDGAR
    30 January 20268-KResults of operations30 January 2026EDGAR
    12 January 20268-KResults of operations, Regulation FD disclosure12 January 2026EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.